Terapia antirretroviral en adultos infectados por VIH

Autores:: Díaz Granados, Carlos A.

Tipo de recurso:: Article of journal

Fecha de publicación:: 2004

Institución:: Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:: Repositorio Digital Institucional ReDi

Idioma:: spa

id	FUCS2_c931501a38d9a9720400d17e1b0dd392
oai_identifier_str	oai:repositorio.fucsalud.edu.co:001/2268
network_acronym_str	FUCS2
network_name_str	Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv	Terapia antirretroviral en adultos infectados por VIH
dc.title.translated.eng.fl_str_mv	Antiretroviral therapy in adults infected with HIV
title	Terapia antirretroviral en adultos infectados por VIH
spellingShingle	Terapia antirretroviral en adultos infectados por VIH
title_short	Terapia antirretroviral en adultos infectados por VIH
title_full	Terapia antirretroviral en adultos infectados por VIH
title_fullStr	Terapia antirretroviral en adultos infectados por VIH
title_full_unstemmed	Terapia antirretroviral en adultos infectados por VIH
title_sort	Terapia antirretroviral en adultos infectados por VIH
dc.creator.fl_str_mv	Díaz Granados, Carlos A.
dc.contributor.author.spa.fl_str_mv	Díaz Granados, Carlos A.
publishDate	2004
dc.date.accessioned.none.fl_str_mv	2004-12-01 00:00:00 2022-02-21T20:35:47Z
dc.date.issued.none.fl_str_mv	2004-12-01
dc.date.available.none.fl_str_mv	2004-12-01 00:00:00 2022-02-21T20:35:47Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.none.fl_str_mv	10.31260/RepertMedCir.v13.n4.2004.361
dc.identifier.issn.none.fl_str_mv	0121-7372
dc.identifier.uri.none.fl_str_mv	https://repositorio.fucsalud.edu.co/handle/001/2268
dc.identifier.eissn.none.fl_str_mv	2462-991X
dc.identifier.url.none.fl_str_mv	https://doi.org/10.31260/RepertMedCir.v13.n4.2004.361
identifier_str_mv	10.31260/RepertMedCir.v13.n4.2004.361 0121-7372 2462-991X
url	https://repositorio.fucsalud.edu.co/handle/001/2268 https://doi.org/10.31260/RepertMedCir.v13.n4.2004.361
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	UNAIDS/WHO. Colombia: Epidemiological fact sheet on HIV/AIDS and sexually transmitted diseases. (Citado 2002). Disponible en: PDF htpp://www.who.int/emchiv/fact sheets/pdfs/Colombia. «Terapia antirretroviral». Disponible en PDF. http://aidsinfo.nih.gov/quidelines/adult/AA 032304. «Terapia antirretroviral».Disponible en PDF. http://www.who.int/hiv/pub/prev care/en/arvrevisionsp. Egger M, May M, Chene et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360(9340):1178 Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Medicine 2003;4(3):255-62. Ahdieh-Grant L, Yamashita TE, Phair JP, et al. When to Initiate Highly Active Antiretroviral Therapy: A Cohort Approach. Am J Epidemiol 2003;157:738-46. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345(6):398-407. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341(25):1865-73. Gulick RM, Ribaudo HJ, Shikuma CM, et al. ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment offlIV infection. In: International AIDS Society Abstracts of the 2 nd Conference on HIV Pathogenesis and Treatment; 2003 Jul 13-16; París Francia. París 1992.Abstractno.41 Cozzi-Lepri A, Phillips AN,D'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals study. J Infect Dis 2002; 185:1062-69. P Keiser, N Nassar, C White, G Koen, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002; 3:296-303. Van Leth F, Phanuphak P, Ruxrugtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004;363: 1253-63. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346(26):2039-46. Sustiva. Package insert. T4-B0001A-10-03. Princenton, NJ, Bristol-Myers Squibb Company: 2003. A phase III study comparing the antiviral efficacy and safety of BMS-232632 (ATV) with efavirenz (EFV), each in combination with fixed doce zidovudine-lamivudine (ZDV+3TC).Princeton, NJ Bristol-Myers Squibb Company. ACTG 384. XIV International AIDS Conference, Barcelona 2002, Abstracts LB20a and LB20b. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33(11):1931-7. New nevirapine label underscores the risk for hepatotoxicity in key populations. AIDS Clinical Care 2004;16(3):2. Maggiolo F, Migliorino M, Pirali A, Pravettoni G, Caprioli S, Suter F. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000;25(1):36-43. Raboud JM, Rae S, Montaner JS. Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups. J Acquir Immune Defic Syndr 2000;24(5):433-9. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
dc.relation.bitstream.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/361/387
dc.relation.citationedition.spa.fl_str_mv	Núm. 4 , Año 2004 : Octubre – Diciembre
dc.relation.citationendpage.none.fl_str_mv	183
dc.relation.citationissue.spa.fl_str_mv	4
dc.relation.citationstartpage.none.fl_str_mv	172
dc.relation.citationvolume.spa.fl_str_mv	13
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía
dc.rights.spa.fl_str_mv	Fundación Universitaria de Ciencias de la Salud FUCS - 0
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Fundación Universitaria de Ciencias de la Salud FUCS - 0 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/361
institution	Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv	https://repositorio.fucsalud.edu.co/bitstreams/cdaf95e8-4feb-415a-8cc3-c55303f4812c/download
bitstream.checksum.fl_str_mv	d8f7a41bb2b378f305b3a88a3bd49ecf
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv	redi@fucsalud.edu.co
_version_	1808413907239305216
spelling	Díaz Granados, Carlos A.c99908862e086e93d3f51465ceac14343002004-12-01 00:00:002022-02-21T20:35:47Z2004-12-012004-12-01 00:00:002022-02-21T20:35:47ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la SaludFundación Universitaria de Ciencias de la Salud FUCS - 0info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/361Terapia antirretroviral en adultos infectados por VIHAntiretroviral therapy in adults infected with HIVapplication/pdfArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/coar/version/c_970fb48d4fbd8a8510.31260/RepertMedCir.v13.n4.2004.3610121-7372https://repositorio.fucsalud.edu.co/handle/001/22682462-991Xhttps://doi.org/10.31260/RepertMedCir.v13.n4.2004.361spaUNAIDS/WHO. Colombia: Epidemiological fact sheet on HIV/AIDS and sexually transmitted diseases. (Citado 2002). Disponible en: PDF htpp://www.who.int/emchiv/fact sheets/pdfs/Colombia.«Terapia antirretroviral». Disponible en PDF. http://aidsinfo.nih.gov/quidelines/adult/AA 032304.«Terapia antirretroviral».Disponible en PDF. http://www.who.int/hiv/pub/prev care/en/arvrevisionsp.Egger M, May M, Chene et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360(9340):1178Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Medicine 2003;4(3):255-62.Ahdieh-Grant L, Yamashita TE, Phair JP, et al. When to Initiate Highly Active Antiretroviral Therapy: A Cohort Approach. Am J Epidemiol 2003;157:738-46.Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345(6):398-407.Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341(25):1865-73.Gulick RM, Ribaudo HJ, Shikuma CM, et al. ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment offlIV infection. In: International AIDS Society Abstracts of the 2 nd Conference on HIV Pathogenesis and Treatment; 2003 Jul 13-16; París Francia. París 1992.Abstractno.41Cozzi-Lepri A, Phillips AN,D'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals study. J Infect Dis 2002; 185:1062-69.P Keiser, N Nassar, C White, G Koen, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002; 3:296-303.Van Leth F, Phanuphak P, Ruxrugtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004;363: 1253-63.Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346(26):2039-46.Sustiva. Package insert. T4-B0001A-10-03. Princenton, NJ, Bristol-Myers Squibb Company: 2003.A phase III study comparing the antiviral efficacy and safety of BMS-232632 (ATV) with efavirenz (EFV), each in combination with fixed doce zidovudine-lamivudine (ZDV+3TC).Princeton, NJ Bristol-Myers Squibb Company.ACTG 384. XIV International AIDS Conference, Barcelona 2002, Abstracts LB20a and LB20b.Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33(11):1931-7.New nevirapine label underscores the risk for hepatotoxicity in key populations. AIDS Clinical Care 2004;16(3):2.Maggiolo F, Migliorino M, Pirali A, Pravettoni G, Caprioli S, Suter F. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000;25(1):36-43.Raboud JM, Rae S, Montaner JS. Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups. J Acquir Immune Defic Syndr 2000;24(5):433-9.Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/361/387Núm. 4 , Año 2004 : Octubre – Diciembre183417213Revista Repertorio de Medicina y CirugíaOREORE.xmltext/xml2483https://repositorio.fucsalud.edu.co/bitstreams/cdaf95e8-4feb-415a-8cc3-c55303f4812c/downloadd8f7a41bb2b378f305b3a88a3bd49ecfMD51001/2268oai:repositorio.fucsalud.edu.co:001/22682022-02-21 15:35:47.311https://creativecommons.org/licenses/by-nc-sa/4.0/Fundación Universitaria de Ciencias de la Salud FUCS - 0metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Terapia antirretroviral en adultos infectados por VIH

Publicaciones similares